Aldara 3M 2000b.

Study characteristics
Methods	This was a phase II research trial. The setting was unclear, but it was multicentre. This study was blinded. Intention‐to‐treat analysis was carried out. This study was conducted in the USA.
Participants	200 participants were recruited. Inclusion criteria of the trial Adults Ordinary warts 'Common warts'
Interventions	5% imiquimod cream Placebo cream Four dosing regimens were included ‐ 3 times weekly with tape occlusion, daily with tape occulusion, 3 times weekly with no tape occulusion, daily with no tape occlusion ‐ versus placebo groups with and without tape occlusion. Warts were pared at interval visits (1‐ to 2‐week intervals). There was 12 weeks of treatment.
Outcomes	Outcomes of the trial Cure at 12 weeks Wart recurrence Adverse effects
Notes	This was unpublished trial data on 'Aldara' cream.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	This study was randomised.
Allocation concealment (selection bias)	Unclear risk	This was unclear.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	'Modified blind' was stated.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	'Modified blind' was stated.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	This was unclear: Intention‐to‐treat analysis and PP analyses were discussed, but the number of dropouts was not stated.
Selective reporting (reporting bias)	Low risk	All prespecified outcomes were reported.